Concord Biotech Ltd - 543960 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015
Pursuant to Regulation 40(9) of SEBI (LODR) Regulation, 2015, We have enclosed a copy of certificate dated 12th April, 2024, Issued by M/S Ashish Shah & Associates, Practicing Company Secretary for the year ended 31st March, 2024. We Request you to Kindly take the same on records Concord Biotech Ltd - 543960 - Reply To Clarification Sought On Volume Movement
We hereby submit that the company has disclosed all the material information/announcement or events from time to time to the exchange which may have bearing on the operation/performance of the company which includes all the necessary disclosures in accordance with regulation 30 of SEBI (LODR) regulation, 2015 and under insider trading regulation, have always been disclosed by the company within stipulated time and the same is available in public domain. There is no pending information or announcement which have a bearing on increase in volume of shares of the company. Therefore, the increase in volume of shares is purely due to market condition and absolutely market driven and the company is in no way connected with any such increase in volume. We hope the above clarifies and request you to kindly take the same on records. Concord Biotech Ltd - 543960 - Clarification sought from Concord Biotech Ltd
The Exchange has sought clarification from Concord Biotech Ltd on April 15, 2024, with reference to Movement in Volume. The reply is awaited. Concord Biotech Ltd - 543960 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with regulation 74(5) of SEBI (depositories and Participants) regulations, 2018, as amended from time to time, we furnish herewith certificate dated 06.04.2024, issued by Link Intime India Private Limited, Registrar and Share transfer agent of the company for the quarter ended March 31, 2024. We request you to kindly take the same as record. Concord Biotech Ltd - 543960 - Closure of Trading Window
In terms of the provisions of the SEBI (Prohibition of Insider Trading) Regulation, 2015 and in compliance with the terms of Code of conduct, the "Trading Window" for dealing in the securities of the company will be closed for all designated persons and their immediate relatives with effect from 01/04/2024 and the same will remain closed till 48 hours after the announcement of financial results for the year and quarter ended on 31/03/2024 to the public. Accordingly, all designated persons of the company and their immediate relatives are advised not to trade in the securities of the company during the aforesaid purpose of closure of trading window. Kindly take the note of same. Concord Biotech Ltd - 543960 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Intimation About EUGMP Certificate Issued By Government Of Upper Franconia For Dholka Facility (Unit I) Of The Company
In compliance with the aforesaid regulation, we hereby notify that Government of Upper Franconia has Issued certificate of Good Manufacturing Practices (EUGMP) for our Unit 1 (API Facility) of the company, located at Trasad Road, Dholka-382225 in Ahmedabad, Gujarat. The certificate is issued for the product "Tacrolimus Premix 20%." Kindly take the above information on records. Concord Biotech Ltd - 543960 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Intimation About GMP Certificate Issued By Brazilian Health Regulatory Agency (ANVISA) At Dholka Facility (Unit I) Of The Company.
In compliance with the aforesaid regulation, we hereby notify that Brazilian Health Regulatory Agency (ANVISA) has issued a Certificate of Good Manufacturing Practices of our Unit 1 (API Facility) of the Company, Located at Trasad Road, Dholka-382225 in Ahmedabad, Gujarat. Kindly take the above information on record. Concord Biotech Ltd - 543960 - Intimation About Closure Of Inspection Of Ministry Of Health Pharmacy And Poisons Board, Republic Of Kenya At Valthera (Unit II) Of The Company
In compliance with the Reg. 30 of LODR, we hereby notify that Ministry of Health Pharmacy and Poisons Board, Republic of Kenya had conducted inspection of Unit II (Formulation facility) of the Company, located at Valthera- Dholka (Unit II) in Ahmedabad, Gujarat. the said inspection has been completed successfully, without any adverse remarks and the company has received the certificate of Good Manufacturing practices (GMP) as on today (i.e. 22/02/2024) Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In Continuation of our letter dated February 09, 2024 regarding audio recording of the unaudited (Standalone and Consolidated) financial results of the company for the Third Quarter and Nine months ended December 31, 2023 , transcripts of the earnings call for the said period enclosed herewith and available on the website of the company at the following link after sending this letter to you, https://www.concordbiotech.com/investors Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be Meeting Investors (Participants) in the enclosed intimation Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This information is submitted to you pursuant to Regulation 30 (6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly note that changes may happen due to exigencies on the part of Host / Participants / Company.